TY - JOUR
T1 - Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema
AU - Fabiani, Claudia
AU - Vitale, Antonio
AU - Emmi, Giacomo
AU - Lopalco, Giuseppe
AU - Vannozzi, Lorenzo
AU - Bacherini, Daniela
AU - Guerriero, Silvana
AU - Favale, Rosa Anna
AU - Fusco, Fiorella
AU - Franceschini, Rossella
AU - Frediani, Bruno
AU - Iannone, Florenzo
AU - Galeazzi, Mauro
AU - Tosi, Gian Marco
AU - Cantarini, Luca
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Purpose: To evaluate the effectiveness and the systemic corticosteroid sparing effect of a single intravitreal dexamethasone (DEX) implant in patients with chronic noninfectious uveitic macular edema (UME). Methods: Data from 22 eyes treated with DEX implant for UME related to systemic or ocular-confined noninfectious diseases were retrospectively analyzed. Results: The mean systemic prednisone (or equivalent) dosage significantly decreased at 3-and 6-month follow-up evaluations compared to baseline (P = 0.002 and P = 0.01, respectively). Compared to baseline, central macular thickness values significantly decreased at 1-, 3-, and 6-month evaluations after the implantation (P < 0.0001). The mean best corrected visual acuity (BCVA) value gradually improved at 1-, 3-, and 6-month visits compared to baseline (P = 0.009, P = 0.0004, and P = 0.0001, respectively). At fluorescein angiography, active retinal vasculitis was identified in 11 (50%) eyes at baseline, 3 (13.6%) eyes at 1-and 3-month follow-up, and in 2 (9.1%) eyes at the last visit. Regarding side effects, 3/22 (13.6%) eyes presented a newly recognized intraocular hypertension at 1-month follow-up; however, intraocular pressure reverted to normal values within the 6-month follow-up in all cases. Conclusions: Treatment with intravitreal DEX implant in noninfectious uveitis allowed a significant corticosteroid sparing effect, a significant improvement in BCVA, and a prompt resolution of UME and vasculitis. No safety issues were observed.
AB - Purpose: To evaluate the effectiveness and the systemic corticosteroid sparing effect of a single intravitreal dexamethasone (DEX) implant in patients with chronic noninfectious uveitic macular edema (UME). Methods: Data from 22 eyes treated with DEX implant for UME related to systemic or ocular-confined noninfectious diseases were retrospectively analyzed. Results: The mean systemic prednisone (or equivalent) dosage significantly decreased at 3-and 6-month follow-up evaluations compared to baseline (P = 0.002 and P = 0.01, respectively). Compared to baseline, central macular thickness values significantly decreased at 1-, 3-, and 6-month evaluations after the implantation (P < 0.0001). The mean best corrected visual acuity (BCVA) value gradually improved at 1-, 3-, and 6-month visits compared to baseline (P = 0.009, P = 0.0004, and P = 0.0001, respectively). At fluorescein angiography, active retinal vasculitis was identified in 11 (50%) eyes at baseline, 3 (13.6%) eyes at 1-and 3-month follow-up, and in 2 (9.1%) eyes at the last visit. Regarding side effects, 3/22 (13.6%) eyes presented a newly recognized intraocular hypertension at 1-month follow-up; however, intraocular pressure reverted to normal values within the 6-month follow-up in all cases. Conclusions: Treatment with intravitreal DEX implant in noninfectious uveitis allowed a significant corticosteroid sparing effect, a significant improvement in BCVA, and a prompt resolution of UME and vasculitis. No safety issues were observed.
KW - dexamethasone
KW - intravitreal implant
KW - macular edema
KW - steroid sparing effec
KW - uveitis
UR - http://www.scopus.com/inward/record.url?scp=85028828145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028828145&partnerID=8YFLogxK
U2 - 10.1089/jop.2017.0034
DO - 10.1089/jop.2017.0034
M3 - Article
AN - SCOPUS:85028828145
VL - 33
SP - 549
EP - 555
JO - Journal of Ocular Pharmacology and Therapeutics
JF - Journal of Ocular Pharmacology and Therapeutics
SN - 1080-7683
IS - 7
ER -